| View |
|
DRP-11163-02
|
Piperacillin (as sodium) + Tazobactam (as sodium)
|
PipzoMax
|
2 g/250 mg
|
Powder for Injection (I.V.)
|
Antibacterial (Penicillin-Beta-Lactamase Inhibitor Combination)
|
Reyoung Pharmaceutical Co., Ltd.
|
China
|
CLIDP Conversion
|
07 March 2023
|
08 February 2027
|
| View |
|
DRP-11163-03
|
Piperacillin (as sodium) + Tazobactam (as sodium)
|
Pipzotam 2.25
|
2 g/ 250mg
|
Powder for Injection (IV)
|
Antibacterial (Penicillin-Beta-Lactamase Inhibitor Combination)
|
Reyoung Pharmaceutical Co., Ltd
|
China
|
CLIDP Conversion
|
22 March 2023
|
08 February 2027
|
| View |
|
DRP-11162-02
|
Piperacillin (as sodium) + Tazobactam (as sodium)
|
PipzoMax 4.5
|
4g/500mg
|
Powder for Injection (IV)
|
Antibacterial (Penicillin-Beta-Lactamase Combination)
|
Reyoung Pharmaceutical Co., Ltd.
|
China
|
CLIDP Conversion
|
07 March 2023
|
08 February 2027
|
| View |
|
DRP-11162-03
|
Piperacillin (as sodium) + Tazobactam (as sodium)
|
Pipzotam 4.5
|
4g/500mg
|
Powder for Injection (IV)
|
Antibacterial (Penicillin-Beta-Lactamase Inhibitor Combination)
|
Reyoung Pharmaceutical Co., Ltd.
|
China
|
CLIDP Conversion
|
22 March 2023
|
08 February 2027
|
| View |
|
DRP-12578-01
|
Oxacillin (as sodium)
|
Oxamax 500
|
500 mg
|
Powder for Injection (IM/IV)
|
Antibacterial (Beta-lactamase resistant penicillin)
|
Reyoung Pharmaceutical
|
China
|
CLIDP Conversion
|
15 March 2023
|
07 September 2027
|
| View |
|
DRP-4198-02
|
Cetirizine (as Hydrochloride)
|
Elbacet
|
5 mg/5 mL
|
Syrup
|
Antihistamine
|
Pharmatec Pakistan (Pvt.) Ltd
|
Pakistan
|
CLIDP Conversion
|
11 September 2023
|
09 June 2026
|
| View |
|
DRP-8635-04
|
Diosmin + Hesperidin
|
Retasmin
|
450 mg/50 mg
|
Film-Coated Tablet
|
Vasoprotective
|
Saga Lifesciences Limited
|
India
|
CLIDP Conversion
|
05 October 2024
|
16 January 2025
|
| View |
|
DRP-12881-03
|
Sitagliptin (as phosphate) + Metformin Hydrochloride
|
Glucomed
|
50 mg/ 500 mg
|
Film-Coated Tablet
|
Antidiabetic Agent (Dipeptidyl peptidase 4 (DPP-4) inhibitor/Biguanide)
|
Eskayef Pharmaceuticals Limited
|
Bangladesh
|
CLIDP Conversion
|
10 October 2024
|
24 October 2027
|
| View |
|
DRP-12738-12
|
Telmisartan + Amlodipine (as besilate)
|
Medivasc
|
40 mg/5 mg
|
Tablet
|
Angiotensin II Receptor Blocker/ Calcium Channel Blocker
|
Evertogen Life Sciences Limited
|
India
|
CLIDP Conversion
|
12 October 2024
|
30 September 2027
|
| View |
|
DRP-15714-01
|
Atorvastatin (as calcium)
|
Gostin-20
|
20 mg
|
Film-Coated Tablet
|
HMG CoA reductase inhibitor
|
Ratnatris Pharmaceuticals Private Limited
|
India
|
CLIDP Conversion
|
12 October 2024
|
06 September 2029
|
| View |
|
DRP-15714-02
|
Atorvastatin (as calcium)
|
Atorvex-20
|
20 mg
|
Film-Coated Tablet
|
HMG CoA reductase inhibitor
|
Ratnatris Pharmaceuticals Private Limited
|
India
|
CLIDP Conversion
|
12 October 2024
|
06 September 2029
|
| View |
|
BRP-128
|
Insulin Human (rDNA)
|
Scilin R
|
100 IU/mL
|
Solution for Injection (IV/SC)
|
Insulin and Analogues
|
Bioton SA
|
Poland
|
Renewal
|
07 October 2024
|
28 January 2030
|
| View |
|
BRP-129
|
Insulin Human (rDNA)
|
Scilin R
|
100IU/mL
|
Solution for Injection (IV/SC)
|
Insulin and Analogues
|
Bioton S.A.
|
Poland
|
Renewal
|
07 October 2024
|
28 January 2030
|
| View |
|
DRP-10511-07
|
Febuxostat
|
Febxuscare
|
80 mg
|
Film-Coated Tablet
|
Antigout
|
Stallion Laboratories Pvt. Ltd.
|
India
|
CLIDP Conversion
|
12 October 2024
|
07 October 2026
|
| View |
|
DRP-10747-02
|
Atorvastatin (as calcium)
|
Fedstatin
|
20 mg
|
Film-Coated Tablet
|
Lipid Modifying Agent (HMG CoA Reductase Inhibitor)
|
Stallion Laboratories Pvt. Ltd
|
India
|
CLIDP Conversion
|
10 October 2024
|
15 November 2026
|
| View |
|
DRP-10748-04
|
Atorvastatin (as calcium)
|
Fedstatin
|
40 mg
|
Film-Coated Tablet
|
Lipid Modifying Agent (HMG CoA Reductase Inhibitor)
|
Stallion Laboratories Pvt. Ltd.
|
India
|
CLIDP Conversion
|
10 October 2024
|
15 November 2026
|
| View |
|
DRP-1100-09
|
Losartan Potassium
|
LOSTAN
|
100 mg
|
Film-Coated Tablet
|
Angiotensin-2-Receptor Blocker
|
J.M. TOLMANN LABORATORIES INC.
|
Philippines
|
CLIDP Conversion
|
13 October 2024
|
17 December 2029
|
| View |
|
DRP-11095-04
|
Sevoflurane
|
Sevomond
|
100 % v/v
|
Volatile Liquid for Inhalation
|
General Anesthetic
|
Hana Pharmaceutical Co., Ltd.
|
Korea
|
CLIDP Conversion
|
07 October 2024
|
28 January 2027
|
| View |
|
DRP-11106-02
|
Co-Amoxiclav
|
Amixlo
|
312.5mg/ 5mL
|
Powder for Oral Suspension (see reverse for formulation)
|
Antibacterial (Penicillin/Beta Lactamase Inhibitor)
|
Medopharm Private Limited
|
India
|
CLIDP Conversion
|
10 October 2024
|
03 February 2027
|
| View |
|
DRP-11780-02
|
Vancomycin (as Hydrochloride)
|
Vancotor
|
500 mg
|
Lyophilized Powder for IV Infusion
|
Antibacterial (Glycopeptide)
|
United Biotech Pvt. Ltd.
|
India
|
CLIDP Conversion
|
12 October 2024
|
21 July 2027
|